
Seoul, South Korea Jul 21, 2025 (Issuewire.com) - Seoul, South Korea Custics, a Korean skincare brand, has launched Lesstopy ATO Cream, a gentle and functional moisturizer formulated for sensitive and eczema-prone skin. Suitable for infants, children, and adults, the cream is designed to soothe irritation and strengthen the skin barrier.
The product features patented Lycopus Lucidus Leaf Extract, a plant-based ingredient known for its calming and skin-repairing properties. It is free from artificial fragrances, artificial colors, and steroids, offering a clean formulation for those seeking safe and effective daily skincare.
"We wanted to develop a product that parents could trust as their child's first moisturizer," said a Custics representative. "Lesstopy ATO Cream reflects our commitment to gentle yet effective care, especially for those with sensitive or eczema-prone skin."
Released earlier this week in South Korea, the product will gradually expand to global markets including Singapore, Hong Kong, Taiwan, Japan, the United States, and the UAE. It will be available through Lesstopy's official website, as well as on Shopee, Amazon, Douyin, Xiaohongshu and Qoo10 Japan, ensuring broad accessibility across major e-commerce and social commerce platforms.
The brand name "Lesstopy", a combination of "Less" and "Atopy", captures Custics' mission to minimize irritation and support healthier skin through safe, science-based formulations.




Media Contact
Glovertise
More On Intelliupdate ::
- Winnie W. Lee, MD: A Board-Certified Surgeon and Aesthetic Expert Blending Beauty and Wellness
- Thomas John Rowland Advocates for Forgotten Dogs and Everyday Action
- Dr. Diane M. Steere: Leading the Way in Compassionate, Comprehensive Family Medicine in Wichita
- Latamclick honored in the Global 100 Awards 2025
- April Suzanne De Vera: Championing Public Health and Advocacy for Children and Youth with Special Healthcare Needs
010-9191-6367
38, Yeongdong-daero 112-gil
Source :Custics
This article was originally published by IssueWire. Read the original article here.